Australia's Neurizon Therapeutics jumps on licensing agreement with Elanco

Neurizon Therapeutics

02/07/2025 03:30

** Shares of Neurizon Therapeutics NUZ.AX rise as much as 3.2% to A$0.160, their biggest intraday pct gain since June 26

** The biotechnology co enters into a global licensing agreement with Elanco Animal Health ELAN.N

** Agreement is for exclusive rights to Elanco's data package and related intellectual property for Monepantel, the active pharmaceutical ingredient in co's NUZ-001, a formulation used in neurodegeneration applications

** YTD, shares of co down 5.9%

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com))